1, 25(OH)2D3 protects β cell against high glucose-induced apoptosis through mTOR suppressing

Molecular and Cellular Endocrinology

Volumn 414, Issue , 2015, Pages 111-119

  Yang, Zesong ^a   Liu, Fang ^a   Qu, Hua ^a   Wang, Hang ^a   Xiao, Xiaoqiu ^a   Deng, Huacong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

1, 25 Dihydroxyvitamin D3; Diabetes mellitus; MTOR; Cell apoptosis

Indexed keywords

CALCITRIOL; CASPASE; CYTOCHROME C; DNA DAMAGE INDUCIBLE TRANSCRIPT 4; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; PROTEIN TSC1; RHEB PROTEIN; S6 KINASE; TUBERIN; UNCLASSIFIED DRUG; MTOR PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE; VITAMIN;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; INHIBITION KINETICS; INS 1 CELL LINE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CYTOLOGY; DIABETES MELLITUS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RAT;

ANIMALS; APOPTOSIS; CALCITRIOL; CELL LINE; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GLUCOSE; INSULIN-SECRETING CELLS; RATS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VITAMINS;

EID: 84938802367     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.07.023     Document Type: Article

References (64)

1. Achiron A., Feldman A., Gurevich M. Characterization of multiple sclerosis traits: nuclear receptors (NR) impaired apoptosis pathway and the role of 1-alpha 25-dihydroxyvitamin D3. J.Neurol. Sci. 2011, 311(1-2):9-14.
2. Akter S., Rahman M.M., Abe S.K., Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. Bull. World Health Org. 2014, 92(3):204-213. 13A.
3. Al-Timimi D.J., Ali A.F. Serum 25(OH) D in diabetes mellitus type 2: relation to glycaemic control. J.Clin. Diagn. Res. 2013, 7(12):2686-2688.
4. Atkinson M.A., Bluestone J.A., Eisenbarth G.S., Hebrok M., Herold K.C., Accili D., et al. How does type 1 diabetes develop?: the notion of homicide or beta-cell suicide revisited. Diabetes 2011, 60(5):1370-1379.
5. Bar-On H., Ben-Sasson R., Ziv E., Arar N., Shafrir E. Irreversibility of nutritionally induced NIDDM in Psammomys obesus is related to beta-cell apoptosis. Pancreas 1999, 18(3):259-265.
6. Bardini G., Giannini S., Romano D., Rotella C.M., Mannucci E. Lipid accumulation product and 25-OH-vitamin D deficiency in type 2 diabetes. Rev. Diab. Stud. 2013, 10(4):243-251.
7. Barreto A.M., Schwartz G.G., Woodruff R., Cramer S.D. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 2000, 9(3):265-270.
8. Bradford M.M. Arapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
9. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102-110.
10. Carstensen B., Jorgensen M.E., Friis S. The epidemiology of diabetes and cancer. Curr. Diab. Rep. 2014, 14(10):535.
11. Cetinkalp S., Delen Y., Karadeniz M., Yuce G., Yilmaz C. The effect of 1alpha,25(OH)2D3 vitamin over oxidative stress and biochemical parameters in rats where Type 1 diabetes is formed by streptozotocin. J.Diab. Complicat. 2009, 23(6):401-408.
12. Choi D., Woo M. Executioners of apoptosis in pancreatic {beta}-cells: not just for cell death. Am. J. Physiol. Endocrinol. Metab. 2010, 298(4):E735-E741.
13. Cudworth A.G. Type I diabetes mellitus. Diabetologia 1978, 14(5):281-291.
14. Datta-Mitra A., Mitra A., Ray R., Raychaudhuri S.P., Kundu-Raychaudhuri S. 1,25-Dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade. Int. Immunopharmacol. 2013, 17(3):744-751.
15. De Haes P., Garmyn M., Degreef H., Vantieghem K., Bouillon R., Segaert S. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J.Cell. Biochem. 2003, 89(4):663-673.
16. Diagnosis and classification of diabetes mellitus. Diab. Care 2006, 29(Suppl.1):S43-S48.
17. Eliaschewitz F.G., Tambascia M.A. Can we prevent beta cell apoptosis in type 2 diabetes?. Diab. Metab. Res. Rev. 2012, 1-17.
18. Fu J., Prasad H.C. Changing epidemiology of metabolic syndrome and type 2 diabetes in Chinese youth. Curr. Diab. Rep. 2014, 14(1):447.
19. Gilbert E.R., Liu D. Epigenetics: the missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes. Epigenetics 2012, 7(8):841-852.
20. Gocek E., Wang X., Liu X., Liu C.G., Studzinski G.P. MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res. 2011, 71(19):6230-6239.
21. Goncharova E.A., Goncharov D.A., Eszterhas A., Hunter D.S., Glassberg M.K., Yeung R.S., et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J.Biol. Chem. 2002, 277(34):30958-30967.
22. Gysemans C.A., Cardozo A.K., Callewaert H., Giulietti A., Hulshagen L., Bouillon R., et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005, 146(4):1956-1964.
23. Habib S.L. Tuberin and mTOR, a key apoptotic pathway in diabetes. Cell Cycle 2011, 10(14):2237-2238.
24. Hamden K., Carreau S., Jamoussi K., Miladi S., Lajmi S., Aloulou D., et al. 1Alpha,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J.Nutr. Sci. Vitaminol. (Tokyo) 2009, 55(3):215-222.
25. Hayes C.E., Nashold F.E., Spach K.M., Pedersen L.B. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 2003, 49(2):277-300.
26. Husemoen L.L., Thuesen B.H., Fenger M., Jorgensen T., Glumer C., Svensson J., et al. Serum 25(OH)D and type 2 diabetes association in a general population: a prospective study. Diab. Care 2012, 35(8):1695-1700.
27. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4(9):648-657.
28. Joost H.G. Diabetes and cancer: epidemiology and potential mechanisms. Diab. Vasc. Dis. Res. 2014, 11(6):390-394.
29. Karunakaran U., Kim H.J., Kim J.Y., Lee I.K. Guards and culprits in the endoplasmic reticulum: glucolipotoxicity and beta-cell failure in type II diabetes. Exp. Diab. Res. 2012, 2012:639762.
30. Kim W.H., Lee J.W., Suh Y.H., Hong S.H., Choi J.S., Lim J.H., et al. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes 2005, 54(9):2602-2611.
31. Kim T.H., Choi S.J., Lee Y.H., Song G.G., Ji J.D. Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis. Med. Hypotheses 2012, 79(6):757-760.
32. Kizildag S., Ates H. Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann. Hematol. 2010, 89(1):1-7.
33. Kwon G., Marshall C.A., Pappan K.L., Remedi M.S., McDaniel M.L. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 2004, 53(Suppl.3):S225-S232.
34. Lee S., Clark S.A., Gill R.K., Christakos S. 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 1994, 134(4):1602-1610.
35. Lim E.L., Hollingsworth K.G., Aribisala B.S., Chen M.J., Mathers J.C., Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54(10):2506-2514.
36. Lisse T.S., Hewison M. Vitamin D: a new player in the world of mTOR signaling. Cell Cycle 2011, 10(12):1888-1889.
37. Lisse T.S., Liu T., Irmler M., Beckers J., Chen H., Adams J.S., et al. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 2011, 25(3):937-947.
38. Lorenz M.A., El Azzouny M.A., Kennedy R.T., Burant C.F. Metabolome response to glucose in the beta-cell line INS-1 832/13. J.Biol. Chem. 2013, 288(15):10923-10935.
39. Marchetti P., Dotta F., Lauro D., Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul. Pept. 2008, 146(1-3):4-11.
40. Mathieu C., Casteels K., Waer M., Laureys J., Valckx D., Bouillon R. Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2. Transpl. Proc. 1998, 30(2):541.
41. Mezza T., Muscogiuri G., Sorice G.P., Prioletta A., Salomone E., Pontecorvi A., et al. Vitamin D deficiency: a new risk factor for type 2 diabetes?. Ann. Nutr. Metab. 2012, 61(4):337-348.
42. Myrthue A., Rademacher B.L., Pittsenbarger J., Kutyba-Brooks B., Gantner M., Qian D.Z., et al. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells. Clin. Cancer Res. 2008, 14(11):3562-3570.
43. Nobukuni T., Joaquin M., Roccio M., Dann S.G., Kim S.Y., Gulati P., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(40):14238-14243.
44. Odegaard J.I., Chawla A. Alternative macrophage activation and metabolism. Annu. Rev. Pathol. 2011, 6:275-297.
45. Porte D. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991, 40(2):166-180.
46. Potter K.J., Westwell-Roper C.Y., Klimek-Abercrombie A.M., Warnock G.L., Verchere C.B. Death and dysfunction of transplanted beta-cells: lessons learned from type 2 diabetes?. Diabetes 2014, 63(1):12-19.
47. Ramos-Lopez E., Lange B., Penna-Martinez M., Bruck P., Swiech K., Mauf S., et al. The role of cubilin gene polymorphisms and their influence on 25(OH)D3 and 1, 25(OH)2D3 plasma levels in type 1 diabetes patients. J.Steroid Biochem. Mol. Biol. 2010, 121(1-2):442-444.
48. Smith E.M., Finn S.G., Tee A.R., Browne G.J., Proud C.G. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J.Biol. Chem. 2005, 280(19):18717-18727.
49. Taylor S.I. Deconstructing type 2 diabetes. Cell 1999, 97(1):9-12.
50. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(21):13571-13576.
51. Thompson L., Wang S., Tawfik O., Templeton K., Tancabelic J., Pinson D., et al. Effect of 25-hydroxyvitamin D3 and 1 alpha,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines. J.Orthop. Res. 2012, 30(5):831-844.
52. Tomita T. Islet amyloid polypeptide in pancreatic islets from type 2 diabetic subjects. Islets 2012, 4(3):223-232.
53. Van Belle T.L., Vanherwegen A.S., Feyaerts D., De Clercq P., Verstuyf A., Korf H., et al. 1,25-Dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell Phenotype in T Cells from type 1 diabetes patients. PLoS One 2014, 9(10):e109194.
54. Velagapudi C., Bhandari B.S., Abboud-Werner S., Simone S., Abboud H.E., Habib S.L. The tuberin/mTOR pathway promotes apoptosis of tubular epithelial cells in diabetes. J.Am. Soc. Nephrol. 2011, 22(2):262-273.
55. Walter M., Kaupper T., Adler K., Foersch J., Bonifacio E., Ziegler A.G. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diab. Care 2010, 33(7):1443-1448.
56. Wang Y., Gao L., Li Y., Chen H., Sun Z. Nifedipine protects INS-1 beta-cell from high glucose-induced ER stress and apoptosis. Int. J. Mol. Sci. 2011, 12(11):7569-7580.
57. Wang S.K., Yang L., Wang T.T., Huang G.L., Yang L.G., Sun G.J. Inhibition of proliferation and induction of apoptosis by the combination of beta-carotene and 1,25-dihydroxyvitamin D3 in human esophageal cancer EC9706 cells. Asian Pac. J. Cancer Prev. 2012, 13(12):6327-6332.
58. Wang L., Yuan T., Du G., Zhao Q., Ma L., Zhu J. The impact of 1,25-dihydroxyvitamin D3 on the expression of connective tissue growth factor and transforming growth factor-beta1 in the myocardium of rats with diabetes. Diab. Res. Clin. Pract. 2014, 104(2):226-233.
59. Xie J., Herbert T.P. The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic beta-cell mass: implications in the development of type-2 diabetes. Cell. Mol. Life Sci. 2012, 69(8):1289-1304.
60. Xu Y., Wang L., He J., Bi Y., Li M., Wang T., et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013, 310(9):948-959.
61. Zella J.B., McCary L.C., DeLuca H.F. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch. Biochem. Biophys. 2003, 417(1):77-80.
62. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J.Clin. Investig. 2003, 112(8):1223-1233.
63. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12(1):21-35.
64. Zou M.S., Yu J., Nie G.M., He W.S., Luo L.M., Xu H.T. 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int. J. Med. Sci. 2010, 7(5):290-299.